Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (not Harrow, Inc., as indicated in the metadata) on January 5, 2015, covering events occurring on January 1, 2015. The filing addresses changes to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignation: August Bassani resigned from the Board of Directors effective January 1, 2015, for personal reasons. The resignation was not due to any disagreement with the Company.
- Director Appointment: Richard L. Lindstrom, M.D., was appointed to the Board of Directors to fill the vacancy left by Mr. Bassani.
- Committee Assignments: Dr. Lindstrom was appointed to the Audit Committee and the Nomination and Corporate Governance Committee. He was also named Chair of the Compensation Committee.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It details Dr. Lindstrom's extensive background in ophthalmology and his prior board service at TearLab Corporation and Ocular Therapeutix, Inc. Additionally, the Company entered into a standard indemnification agreement with Dr. Lindstrom and confirmed his eligibility for the standard non-employee director cash compensation program ($40,000 annual retainer).
Investor Verification Checklist
- Verify the correct registrant name is Imprimis Pharmaceuticals, Inc., not Harrow, Inc.
- Confirm the effective date of the board changes (January 1, 2015).
- Review Dr. Lindstrom's full biographical details and potential conflicts of interest given his service on other public company boards.
- Check the Company's Definitive Proxy Statement (filed August 8, 2014) for details on the director compensation program.